

26th September 2024

Dear Clinician,

RE: ANTICIPATED SHORTAGE OF PEGASYS® (peginterferon alfa-2a) IN AUSTRALIA

Echo Therapeutics Pty Ltd is the registered sponsor of a number of pharmaceutical products listed on the Australian Register of Therapeutic Goods (ARTG), including Pegasys® (peginterferon alfa-2a) [AUST R 91836 and 91879]. **Due to an unexpected and ongoing increase in local demand for Pegasys®, we regret to inform you that we have formally notified the Therapeutic Goods Administration (TGA) of an anticipated shortage of the product in Australia.**

We are currently in the process of notifying wholesalers and patients about this development. We appreciate this is difficult news for clinicians and patients to hear. Please be assured that Echo Therapeutics remains committed to the local patient community and is doing everything possible to prioritise the supply of Pegasys® for Australian patients living with Myeloproliferative Neoplasms (MPNs).

As per our previous correspondence (dated August 2024), supply of Pegasys® to hospitals will be via an existing wholesaler channel, while community-based patients can continue to access their treatment directly through the **Pegasys® Home Delivery Program**, via [JustMeds](#).

We currently have stock in the country to continue to meet your patients' needs and are hopeful of another Pegasys® shipment arriving in Australia before the end of the year. To ensure fair and equitable distribution of available stock, we request your assistance in encouraging patients to only get one month's supply of treatment dispensed at a time – except in exceptional circumstances, such as a patient who may be travelling.

Thank you for your continued understanding and support as Echo Therapeutics works to minimise the impact of any anticipated Pegasys® shortage on Australian patients. Please don't hesitate to contact us on customerservice@echotherapeutics.net or **1300 84 83 28**, should you have any questions.

We will continue to keep you updated on any further developments, and look forward to engaging with you at Blood 2024.

Yours sincerely,



Jude D'Silva
Managing Director
GAICD



w: www.echotherapeutics.com.au